Prasugrel development - claims and achievements

Area of Science:

• Pharmacology
• Cardiovascular Medicine
• Drug Development

Background:

• Oral antiplatelet agents like aspirin and clopidogrel offer significant mortality reduction in acute vascular thrombotic events.
• Prasugrel, an ADP P2Y(12) receptor antagonist, inhibits platelet activation and aggregation.
• The TRITON trial compared prasugrel with clopidogrel, but raised concerns regarding its design and interpretation.

Purpose of the Study:

• To critically review the development of prasugrel, an experimental antiplatelet agent.
• To analyze discrepancies between claimed benefits and actual achievements of prasugrel.
• To evaluate the suitability of prasugrel's high maintenance dose for chronic use.

Main Methods:

• Critical review of prasugrel development data.
• Analysis of the TRITON trial, comparing prasugrel and clopidogrel.
• Evaluation of trial design, event definitions, and result interpretation.

Main Results:

• Significant controversies surround the TRITON trial's design, event definitions, and result interpretation.
• The benefits of prasugrel appear to be overestimated.
• The risks associated with prasugrel, particularly during chronic use, are underestimated.

Conclusions:

• There is a need for careful selection of maintenance doses for new antiplatelet agents.
• Long-term safety profiles are paramount for the successful development of future oral antiplatelet drugs.
• Current evidence suggests prasugrel's benefits may be overstated and its risks underestimated for chronic use.